For lease · Roorkee, Uttarakhand · Ref LGP-RK-01
GMP Pharma Unit for Rent in Roorkee — 9,000 sq ft for Tablets, Capsules and Liquid Orals
A running, licensed formulation unit on the Delhi–Haridwar–Dehradun road axis, offered on lease at INR 4,00,000 per month. Below: the full specification as represented by the operator, the three commercial routes this facility can be taken on, and the twelve things to verify before you sign anything.
Facility at a glance
Every figure in this table is as represented by the operator and has not been independently audited by Laafon Galaxy. Treat it as the starting point for diligence, not as a verified record.
| Location | Roorkee, District Haridwar, Uttarakhand |
| Offer type | Lease / rent of a running licensed unit |
| Monthly rent | INR 4,00,000 (deposit, lock-in, escalation and exit terms not yet disclosed) |
| Land area | 1,400 square yards |
| Covered area | 9,000 square feet |
| Dosage forms | Tablets (non-beta-lactam), capsules (non-beta-lactam), liquid orals |
| Approved formulations | More than 250 |
| Certification stated | GMP — certifying authority, scope and certificate number not published |
| Licence validity stated | Up to 2028. Manufacturing licences in Uttarakhand are granted by the State Licensing Authority under the Food Safety and Drug Administration, Uttarakhand [1] |
| Commissioned | 2021 |
| Workforce on site | 25 |
| Current occupancy | Operating for 20 third-party manufacturing clients |
| Legal entity | Partnership firm |
Renting the premises is not the only way to use this unit
Three different arrangements are commonly described as taking a unit on rent, and they carry very different licence positions, lead times and liability. Pick the two answers that describe you and the block below names the route that fits, together with the licence instrument it runs on.
Answer both questions above
The route changes the licence you hold, who carries GMP liability for the premises, and how long you wait before the first batch can be released.
Background reading on the three models sits on pharma business models in India, and the loan-licence route specifically on our loan licence consulting page.
What each route actually costs you
Timelines are indicative and depend on the State Licensing Authority’s current queue and on how complete your application is. They are not commitments.
| Point of comparison | Lease the premises | Loan licence | Third-party manufacturing |
|---|---|---|---|
| Licence you hold | Your own Form 25, applied for on these premises | Form 25A loan licence, applied for in Form 24A, granted against the host unit’s approved premises [2] | None — the manufacturer’s licence covers the batch |
| Whose name is on the label | Yours, as manufacturer | Yours, manufactured at the host premises | Manufactured by the host, marketed by you |
| Who carries GMP liability for the site | You, once the licence is transferred to you | Shared — the premises stay the host’s responsibility, the product is yours | The host manufacturer |
| Typical lead time to first batch | Longest — premises inspection plus licence grant | Shorter — premises are already approved | Shortest — no licence step for you |
| Monthly commitment | INR 4,00,000 rent plus payroll, utilities and QC running cost | Loan-licence fee plus per-batch conversion cost | Per-batch conversion cost only |
| Control over scheduling | Full | Partial — you queue alongside the host’s own work | Least |
| Exit | Lease notice period, plus licence surrender or transfer | End of the loan-licence term | End of the purchase order |
Scroll the table sideways on a phone
Section-wise capacity and equipment
Output figures below are per eight-hour shift, as stated by the operator. Sustained output depends on batch size, changeover time, and how much of the line the existing 20 clients are already consuming.
Tablet section
Non-beta-lactam only. Two rotary compression machines feed a double-track blister line and a double-track alu-alu line, so both blister and alu-alu packing are available in house.
Equipment naming conventions and what a complete section should contain are set out in our pharma machinery list for tablet, capsule and liquid sections.
Capsule section
Non-beta-lactam only. One capsule filling machine with loader. Capsule output shares the blister and alu-alu packing lines with the tablet section, so packing capacity, not filling capacity, is usually the real constraint.
Liquid orals section
A four-head liquid filling line. Bottle size is not stated, and 20,000 bottles per shift means something very different at 60 ml than at 200 ml — confirm the size the figure is based on before you model throughput.
Why Roorkee, and what changed in 2026
The corridor opened in April 2026
The Delhi–Dehradun Economic Corridor was inaugurated on 14 April 2026 and runs via Ghaziabad, Baghpat, Baraut, Shamli and Saharanpur [3]. Roorkee sits on the Saharanpur–Haridwar side of that axis, which shortens the road run to the Delhi NCR distributor base and to Delhi airport for export consignments. Confirm the actual site-to-corridor distance on your site visit rather than relying on a listing claim.
Who licenses this unit
Uttarakhand manufacturing licences are granted and renewed by the State Licensing Authority under the Food Safety and Drug Administration, Uttarakhand [1]. If you take the premises on lease and apply for your own licence, that is the office you deal with — and the office that will inspect the site before granting it.
Twelve things to verify before you sign
A rented licensed unit transfers the premises’ compliance history to you along with its equipment. Work through this list before money moves. Tick items off as you clear them — the list resets when you reload.
Buying rather than renting changes the list substantially. The longer version sits in our 50-point pharma plant acquisition checklist.
Five things this listing does not yet answer
Stating these plainly is more useful than filling them with adjectives. We are pursuing each with the operator and will update this page as answers arrive.
- GMP scope. The unit is described as GMP certified. Whether that is a state Schedule M certificate, a WHO-GMP certificate, or both, and which sections it covers, has not been disclosed.
- Licence particulars. The licence number and issuing office behind the claim of validity to 2028 have not been published, so the claim cannot yet be checked against the state record.
- Capacity actually available. With 20 clients already served, the share of the stated capacity a new lessee would genuinely control is unknown.
- Lease commercials. Deposit, lock-in period, escalation, exit terms and the inclusions behind INR 4,00,000 a month have not been detailed.
- Schedule M readiness. The premises’ position against the revised Schedule M as at the January 2026 enforcement date has not been stated [4].
Questions buyers ask about this unit
The quoted rent is INR 4,00,000 per month for the licensed unit. The deposit, lock-in period, annual escalation and what the figure includes by way of power, water, effluent treatment, the QC laboratory and the 25 staff on site have not been disclosed, so treat the headline figure as the starting point of a negotiation rather than the total monthly cost.
Yes, by two different routes. You can lease the premises and apply for a manufacturing licence of your own on that address, which means a fresh inspection by the State Licensing Authority. Or you can take a loan licence, which is granted to you to manufacture at premises already approved in the host’s name. Because this unit makes tablets, capsules and liquid orals, the applicable loan licence is Form 25A, applied for in Form 24A.
Tablets and capsules in the non-beta-lactam category, and liquid orals. More than 250 formulations are stated as approved. The unit has no injectable, dry powder injection, beta-lactam, cephalosporin or hormone facility, and none of those can be added without a separate, physically segregated block and a fresh licence endorsement.
Running. It is stated to serve 20 third-party manufacturing clients with 25 people on site, and was commissioned in 2021. That is reassuring for equipment condition and staff availability, but it also means capacity is already committed. Establish in writing how much of the line you would actually control before you model output or promise delivery dates to your own customers.
It affects the premises, and you occupy the premises. The compliance timeline for smaller manufacturers was extended by notification G.S.R. 10(E) of 4 January 2025 to 31 December 2025, with enforcement following from 1 January 2026. Ask the operator what upgrade was carried out, what documentation exists, and whether any observation is still open, before the compliance history becomes yours to answer for.
It depends entirely on the route. Third-party manufacturing is quickest because no licence step sits between you and the batch. A loan licence is next, because the premises are already approved and only your application has to be processed. Leasing and applying for your own licence is the slowest, because a fresh premises inspection is involved. Actual timelines track the State Licensing Authority’s queue and the completeness of your file, so no honest figure can be promised in advance.
Yes. Alongside this rental unit we list a pharma plant for sale in Roorkee, an injectable unit in Uttarakhand and a nutraceutical and food unit in the same state. Rental options in other states are collected on the pharma unit for rent in India page.
Renting keeps capital free and caps the downside if the product range does not work, at the cost of never owning the asset and depending on a landlord’s compliance record. Buying costs far more upfront but gives you the licence, the premises and the exit. If you are weighing the two, the cost side of ownership is set out in our pharma manufacturing plant cost breakdown, and current sale listings sit on pharma plants for sale.
Related on Laafon
- Pharma unit for rent in India — rental units listed across other states.
- Loan licence consulting — if you want your own licence without taking on premises.
- Third-party manufacturing — the route with no licence and no lease.
- Regulatory compliance consultation — help with the licence application and the inspection that precedes it.
- 50-point acquisition checklist — the full diligence list if you shift from renting to buying.
- Pharma business models in India — PCD, third-party and own-plant compared end to end.
Request the licence copy, GMP certificate and lease terms
Send your product range and target monthly volumes and we will come back with the documents listed above, the inclusions behind the rent, and whether a loan licence or a lease fits your case better.
- Food Safety and Drug Administration, Uttarakhand. Drugs and Cosmetics — Licences and Registration. Dehradun: Government of Uttarakhand. Available from: fda.uk.gov.in/drug-cosmetics-licenses-and-registration Accessed September 2026.
- Drugs and Cosmetics Rules, 1945, Schedule A. Form 24A, application for grant of a loan licence to manufacture for sale or distribution of drugs other than those specified in Schedules C, C(1) and X; Form 25A, the loan licence itself. Form descriptions as indexed by The Health Master forms directory (secondary source — verify against the bare Rules before filing). Available from: thehealthmaster.com/forms-drugs Accessed September 2026.
- Press Information Bureau, Government of India. Prime Minister Shri Narendra Modi inaugurates Delhi–Dehradun Economic Corridor. New Delhi: PIB; 14 April 2026. Available from: pib.gov.in — PRID 2251855 Accessed September 2026.
- Ministry of Health and Family Welfare, Government of India. Notification G.S.R. 10(E), 4 January 2025 — extension of the timeline for compliance with the revised Schedule M for manufacturers with turnover of INR 250 crore or less, to 31 December 2025, with enforcement from 1 January 2026. Summarised by CliniExperts regulatory update (secondary source — verify against the e-Gazette text before relying on it). Available from: cliniexperts.com — revised Schedule M timeline extension Accessed September 2026.
All facility details on this page are as represented by the operator and have not been independently audited by Laafon Galaxy Pharmaceuticals. Nothing here is an offer, a valuation, or legal, regulatory or investment advice. Indian statutory instruments, state licensing practice and pharmacopoeial requirements change frequently; verify every regulatory position against the instrument in force at the time you act, and take independent professional advice before committing funds.